Nicolas Sayegh

21PUBLICATIONS
50CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Rural and remote health servicesPlanning and decision making
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (21)

|Dec 04, 2025
Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate Cancer.

Nicolas Sayegh, Ryon P Graf, Umang Swami

|Jul 28, 2025
Precision and Combination Strategies for Immune Checkpoint Inhibitors in Prostate Cancer.

Nicolas Sayegh, Zeynep Irem Ozay, Tian Zhang

|Jun 16, 2025
Association of Homologous Recombination Repair Alterations with Outcomes in Patients with Metastatic Hormone-Sensitive Prostate Cancer.

Chadi Hage Chehade, Ryon P Graf, Zeynep Irem Ozay

|Mar 21, 2025
Histone Deacetylase Inhibitors in the Management of Advanced Cancers.

Nicolas Sayegh, Valerie Etzrodt

|Jan 30, 2025
Genomic biomarkers of survival in patients with metastatic hormone-sensitive prostate cancer undergoing intensified androgen deprivation therapy.

Georges Gebrael, Nicolas Sayegh, Chadi Hage Chehade

|Jan 10, 2025
A pan-tumor review of the role of poly(adenosine diphosphate ribose) polymerase inhibitors.

Chadi Hage Chehade, Georges Gebrael, Nicolas Sayegh

Pageof 4